Adamas Pharmaceuticals (NASDAQ:ADMS) and RegeneRx Biopharmaceuticals (OTCMKTS:RGRX) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, valuation, analyst recommendations, risk, dividends, profitability and institutional ownership.
Insider and Institutional Ownership
63.4% of Adamas Pharmaceuticals shares are held by institutional investors. Comparatively, 0.1% of RegeneRx Biopharmaceuticals shares are held by institutional investors. 24.9% of Adamas Pharmaceuticals shares are held by company insiders. Comparatively, 10.9% of RegeneRx Biopharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
This is a summary of current recommendations for Adamas Pharmaceuticals and RegeneRx Biopharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Adamas Pharmaceuticals currently has a consensus price target of $18.44, indicating a potential upside of 356.55%. Given Adamas Pharmaceuticals’ higher possible upside, equities analysts plainly believe Adamas Pharmaceuticals is more favorable than RegeneRx Biopharmaceuticals.
Risk and Volatility
Adamas Pharmaceuticals has a beta of 1.6, indicating that its stock price is 60% more volatile than the S&P 500. Comparatively, RegeneRx Biopharmaceuticals has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500.
This table compares Adamas Pharmaceuticals and RegeneRx Biopharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Valuation and Earnings
This table compares Adamas Pharmaceuticals and RegeneRx Biopharmaceuticals’ revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adamas Pharmaceuticals||$34.05 million||3.30||-$131.00 million||($4.87)||-0.83|
|RegeneRx Biopharmaceuticals||$70,000.00||263.01||-$1.99 million||N/A||N/A|
RegeneRx Biopharmaceuticals has lower revenue, but higher earnings than Adamas Pharmaceuticals.
Adamas Pharmaceuticals beats RegeneRx Biopharmaceuticals on 8 of the 11 factors compared between the two stocks.
Adamas Pharmaceuticals Company Profile
Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.
RegeneRx Biopharmaceuticals Company Profile
RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, Thymosin beta 4 (Tß4), for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It also evaluates the commercial development of peptide fragments and derivatives of Tß4 for potential cosmeceutical and other personal care uses. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was founded in 1982 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.